{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["333(16)"],"submitter":["Thouvenot E"],"pubmed_abstract":["<h4>Importance</h4>Vitamin D deficiency is a risk factor for multiple sclerosis (MS) and is associated with the risk of disease activity, but data on the benefits of supplementation are conflicting.<h4>Objective</h4>To evaluate the efficacy of high-dose cholecalciferol as monotherapy in reducing disease activity in patients with clinically isolated syndrome (CIS) typical for MS.<h4>Design, setting, and participants</h4>The D-Lay MS trial was a parallel, double-blind, randomized placebo-controlled clinical trial in 36 MS centers in France. Patients were enrolled from July 2013 to December 2020 (final follow-up on January 18, 2023). Untreated patients with CIS aged 18 to 55 years with CIS duration less than 90 days, serum vitamin D concentration less than 100 nmol/L, and diagnostic magnetic "],"journal":["JAMA"],"pagination":["1413-1422"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11894546"],"repository":["biostudies-literature"],"pubmed_title":["High-Dose Vitamin D in Clinically Isolated Syndrome Typical of Multiple Sclerosis: The D-Lay MS Randomized Clinical Trial."],"pmcid":["PMC11894546"],"pubmed_authors":["Collongues N","Castelnovo G","Le Page E","Camu W","Taithe F","Heinzlef O","Devy R","Lejeune F","Derache N","Moreau T","Rival M","Casez O","Gaillard N","Laplaud D","Tourbah A","Vukusic S","Biotti D","Wiertlewski S","Ciron J","Thouvenot E","Galanaud D","Ayrignac X","Papeix C","Patry I","Guennoc AM","Maillart E","Schunck A","Renard D","Deburghgraeve V","Dubessy Anne L","Clavelou P","Michel L","Ungureanu A","Hautecoeur P","Calais G","Aufauvre D","Talmant V","Magy L","Edan G","Delalande L","Faighel M","Mas J","Montcuquet A","Lancin Garcia C","Froment-Tilikete C","Brassat D","De Seze J","Benoilid A","Durand-Dubief F","Kerbat A","Outteryck O","Bourre B","Demattei C","D-Lay MS Investigators","Mura T","Maarouf A","Yeung J","Nifle C","Louapre C","Cohen M","Biberon J","Lebrun-Frenay C","Fromont A","Gout O","Agherbi H","Pittion-Vouyovitch S","Couloume L","Deschamps R","Carra Dalliere C","Wacongne A","Vaillant M","Coustans M","Caucheteux N","Fabbro-Peray P"],"additional_accession":[]},"is_claimable":false,"name":"High-Dose Vitamin D in Clinically Isolated Syndrome Typical of Multiple Sclerosis: The D-Lay MS Randomized Clinical Trial.","description":"<h4>Importance</h4>Vitamin D deficiency is a risk factor for multiple sclerosis (MS) and is associated with the risk of disease activity, but data on the benefits of supplementation are conflicting.<h4>Objective</h4>To evaluate the efficacy of high-dose cholecalciferol as monotherapy in reducing disease activity in patients with clinically isolated syndrome (CIS) typical for MS.<h4>Design, setting, and participants</h4>The D-Lay MS trial was a parallel, double-blind, randomized placebo-controlled clinical trial in 36 MS centers in France. Patients were enrolled from July 2013 to December 2020 (final follow-up on January 18, 2023). Untreated patients with CIS aged 18 to 55 years with CIS duration less than 90 days, serum vitamin D concentration less than 100 nmol/L, and diagnostic magnetic ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2026-06-02T17:45:46.586Z","creation":"2026-05-27T03:07:42.928Z"},"accession":"S-EPMC11894546","cross_references":{"pubmed":["40063041"],"doi":["10.1001/jama.2025.1604"]}}